Morocco's Laprophan IPO seven times oversubscribed, lead manager says

Resumen detallado
RABAT- Moroccan pharmaceutical company Laprophan's initial public offering was seven times oversubscribed, reflecting strong investor demand for the largest listing on the…
* Investors submitted orders worth 15.3 billion dirhams ($1.5 billion) for an offer seeking to raise 2.22 billion dirhams, according to final estimates from Bachir Tazi, executive director at CFG Bank, the IPO's lead manager
* The IPO, Morocco's third this year, combines the sale of a mix of new and existing shares
* Laprophan, which operates four industrial sites in Morocco and Switzerland, reported revenue of 1.82 billion dirhams ($180 million) in 2025, up from 1.638 billion dirhams a year earlier
* The IPO is intended to support expansion plans, including the acquisition of Polymedic, another Moroccan pharmaceutical company that generated revenue of about 405 million dirhams in 2025, subject to regulatory approval
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here
Inicio del artículo, extracto de Zawya. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.zawya.com)



